Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBIT (2019 - 2025)

Pulmonx (LUNG) has disclosed EBIT for 7 consecutive years, with -$14.4 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 1.87% to -$14.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$57.2 million, a 1.77% increase, with the full-year FY2024 number at -$57.7 million, up 6.83% from a year prior.
  • EBIT was -$14.4 million for Q3 2025 at Pulmonx, up from -$14.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$9.8 million in Q3 2021 to a low of -$16.4 million in Q2 2023.
  • A 5-year average of -$14.1 million and a median of -$14.4 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 104.69% in 2021, then increased 11.37% in 2024.
  • Pulmonx's EBIT stood at -$12.4 million in 2021, then decreased by 18.28% to -$14.6 million in 2022, then increased by 4.84% to -$13.9 million in 2023, then grew by 3.61% to -$13.4 million in 2024, then dropped by 7.27% to -$14.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBIT are -$14.4 million (Q3 2025), -$14.8 million (Q2 2025), and -$14.6 million (Q1 2025).